Stock Scorecard
Stock Summary for Madrigal Pharmaceuticals Inc (MDGL) - $459.73 as of 2/6/2026 4:45:02 PM EST
Total Score
6 out of 30
Safety Score
50 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MDGL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MDGL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MDGL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for MDGL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for MDGL (50 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for MDGL
Financial Details for MDGL
Company Overview |
|
|---|---|
| Ticker | MDGL |
| Company Name | Madrigal Pharmaceuticals Inc |
| Country | USA |
| Description | Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in West Conshohocken, Pennsylvania, focused on developing innovative therapies for cardiovascular, metabolic, and liver diseases. The company's lead candidate, resmetirom, is specifically designed to address non-alcoholic steatohepatitis (NASH), targeting a significant unmet need in an expanding patient demographic. With a robust pipeline and encouraging clinical trial results, Madrigal is positioned as a promising player in the metabolic disease sector, presenting an attractive opportunity for institutional investors seeking to invest in transformative healthcare solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/25/2026 |
Stock Price History |
|
| Last Day Price | 459.73 |
| Price 4 Years Ago | 290.25 |
| Last Day Price Updated | 2/6/2026 4:45:02 PM EST |
| Last Day Volume | 382,883 |
| Average Daily Volume | 315,708 |
| 52-Week High | 615.00 |
| 52-Week Low | 265.00 |
| Last Price to 52 Week Low | 73.48% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.21 |
| Sector PE | 34.82 |
| 5-Year Average PE | -21.09 |
| Free Cash Flow Ratio | 35.31 |
| Industry Free Cash Flow Ratio | 12.52 |
| Sector Free Cash Flow Ratio | 33.33 |
| Current Ratio Most Recent Quarter | 3.44 |
| Total Cash Per Share | 13.02 |
| Book Value Per Share Most Recent Quarter | 27.56 |
| Price to Book Ratio | 17.96 |
| Industry Price to Book Ratio | 53.70 |
| Sector Price to Book Ratio | 53.77 |
| Price to Sales Ratio Twelve Trailing Months | 15.02 |
| Industry Price to Sales Ratio Twelve Trailing Months | 21.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.66 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 22,711,400 |
| Market Capitalization | 10,441,111,922 |
| Institutional Ownership | 104.55% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 10.80% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -24.69% |
| Reported EPS 12 Trailing Months | -12.90 |
| Reported EPS Past Year | -10.18 |
| Reported EPS Prior Year | -22.11 |
| Net Income Twelve Trailing Months | -289,125,000 |
| Net Income Past Year | -465,892,000 |
| Net Income Prior Year | -373,630,000 |
| Quarterly Revenue Growth YOY | 362.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | -39.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 295,694,000 |
| Total Cash Past Year | 100,019,000 |
| Total Cash Prior Year | 99,915,000 |
| Net Cash Position Most Recent Quarter | -44,059,000 |
| Net Cash Position Past Year | -17,550,000 |
| Long Term Debt Past Year | 117,569,000 |
| Long Term Debt Prior Year | 115,480,000 |
| Total Debt Most Recent Quarter | 339,753,000 |
| Equity to Debt Ratio Past Year | 0.87 |
| Equity to Debt Ratio Most Recent Quarter | 0.65 |
| Total Stockholder Equity Past Year | 754,383,000 |
| Total Stockholder Equity Prior Year | 405,333,000 |
| Total Stockholder Equity Most Recent Quarter | 625,732,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -161,631,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -7.12 |
| Free Cash Flow Past Year | -457,034,000 |
| Free Cash Flow Prior Year | -325,709,000 |
Options |
|
| Put/Call Ratio | 0.40 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 379.31 |
| 20-Day Bollinger Middle Band | 506.81 |
| 20-Day Bollinger Upper Band | 634.31 |
| Beta | -1.02 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/3/2026 10:33:22 PM EST |